Clinical-stage biotech company Rhythm Pharmaceuticals, backed by France-based pharmaceutical company Ipsen, has filed to raise up to $86m in an IPO.
US-based biotech company Rhythm Pharmaceuticals has filed to raise up to $86m in an IPO.
Founded in 2008, Rhythm develops peptide therapeutics for the treatment of obesity, diabetes, gastroparesis and other gastrointestinal functional disorders.
The company, which initially filed for an offering in July, which use the capital raised to develop and manufacture drugs for the treatment of diabetic gastroparesis and Prader Willi Syndrome.
Citigroup and Cowen & Company will serve as lead underwriters for the deal.
Rhythm…
